224 related articles for article (PubMed ID: 31247322)
21. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
[TBL] [Abstract][Full Text] [Related]
22. Impact of Morphological Sectors on Antifungal Susceptibility Testing and Virulence Studies.
Jukic E; Blatzer M; Binder U; Mayr L; Lass-Flörl C; Lackner M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993330
[TBL] [Abstract][Full Text] [Related]
23. Galleria mellonella as a host model to study Aspergillus terreus virulence and amphotericin B resistance.
Maurer E; Browne N; Surlis C; Jukic E; Moser P; Kavanagh K; Lass-Flörl C; Binder U
Virulence; 2015; 6(6):591-8. PubMed ID: 26107350
[TBL] [Abstract][Full Text] [Related]
24. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
25. Aspergillus terreus Species Complex.
Lass-Flörl C; Dietl AM; Kontoyiannis DP; Brock M
Clin Microbiol Rev; 2021 Dec; 34(4):e0031120. PubMed ID: 34190571
[TBL] [Abstract][Full Text] [Related]
26. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility.
Speth C; Blum G; Hagleitner M; Hörtnagl C; Pfaller K; Posch B; Ott HW; Würzner R; Lass-Flörl C; Rambach G
Med Microbiol Immunol; 2013 Oct; 202(5):379-89. PubMed ID: 23722593
[TBL] [Abstract][Full Text] [Related]
27. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
Lewis RE; Albert NP; Liao G; Wang W; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2013 May; 68(5):1148-51. PubMed ID: 23349440
[TBL] [Abstract][Full Text] [Related]
28. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
29. Aspergillus species intrinsically resistant to antifungal agents.
Van Der Linden JW; Warris A; Verweij PE
Med Mycol; 2011 Apr; 49 Suppl 1():S82-9. PubMed ID: 20662634
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
32. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
Chamilos G; Kontoyiannis DP
Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
[TBL] [Abstract][Full Text] [Related]
33. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
34. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin.
Cooke FJ; Terpos E; Boyle J; Rahemtulla A; Rogers TR
Clin Microbiol Infect; 2003 Dec; 9(12):1238-41. PubMed ID: 14686991
[TBL] [Abstract][Full Text] [Related]
35. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
Graybill JR; Kaster SR
Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
[TBL] [Abstract][Full Text] [Related]
36. Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.
Madaan K; Bari VK
Microb Drug Resist; 2023 Aug; 29(8):319-332. PubMed ID: 37327022
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
Sionov E; Mendlovic S; Segal E
J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
Silvanose CD; Bailey TA; Di Somma A
Vet Rec; 2006 Aug; 159(9):282-4. PubMed ID: 16946311
[TBL] [Abstract][Full Text] [Related]
39. Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing.
Kathuria S; Sharma C; Singh PK; Agarwal P; Agarwal K; Hagen F; Meis JF; Chowdhary A
PLoS One; 2015; 10(3):e0118997. PubMed ID: 25781896
[TBL] [Abstract][Full Text] [Related]
40. Treatment of murine systemic aspergillosis with polyene-intralipid admixtures.
Sionov E; Segal E
Med Mycol; 2004 Feb; 42(1):73-80. PubMed ID: 14982116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
